Status:
ACTIVE_NOT_RECRUITING
Phase-Aligned Atrial Fibrillation Mapping
Lead Sponsor:
Larisa Tereshchenko, MD, PhD
Collaborating Sponsors:
American Heart Association
Conditions:
Atrial Fibrillation (AF)
Eligibility:
All Genders
18-89 years
Brief Summary
Cardiac arrhythmia in the upper chamber of the heart (atrial fibrillation) can be cured by burning. Physicians burn very small pieces of abnormal tissue. It is important to know where to burn. The inv...
Detailed Description
Atrial fibrillation (AF) ablation is an important treatment strategy, potentially capable of curing AF. However, there is a variable degree of success of the persistent AF ablation procedure. Therefor...
Eligibility Criteria
Inclusion
- Records of patients with persistent AF who underwent pulmonary vein isolation (PVI) with any additional AF ablation strategy with available stored digital AF mapping data. Persistent AF is defined as AF lasting more than 7 days.
- One/First AF ablation procedure (no prior atrial ablation procedures)
- Documented complete pulmonary vein isolation at the end of the ablation
- Available uniform, high-quality (as described below) clinical data required to detect AF recurrence during ≥ 1 year after ablation, and/or ECG monitoring (implantable loop recording or repeated long-term ECG monitoring via ECG patch or similar)
Exclusion
- Familial AF, AF as a syndrome in rare diseases (cardiomyopathies / WPW/ channelopathies).
- Missing data of exposure (AF ablation map), outcome (definition of cases and controls), or covariates
Key Trial Info
Start Date :
August 16 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 16 2026
Estimated Enrollment :
336 Patients enrolled
Trial Details
Trial ID
NCT06892561
Start Date
August 16 2023
End Date
August 16 2026
Last Update
January 5 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cleveland Clinic
Cleveland, Ohio, United States, 44195